OncoMatch/Clinical Trials/NCT02259556
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Is NCT02259556 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CART30 for hodgkin's lymphoma.
Treatment: CART30 — Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors. In this trial, CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma will be treated by CD30-specific CART cells (CART30).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD30 overexpression (positive)
CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma
Demographics
Prior therapy
Must have received: autologous stem cell transplant — relapsed
relapsing after autologous stem-cell transplantation (ASCT)
Must have received: cytotoxic chemotherapy — refractory
refractory to 2 multidrug regimens
Must have received: anti-CD30 antibody — refractory
refractory to ... anti-CD30 antibody treatment
Cannot have received: anti-CD30 antibody
Exception: within recent 6 weeks
Receive anti-CD30 antibody-based therapy within recent 6 weeks
Lab requirements
Kidney function
Creatinine <2.5mg/dl
Liver function
ALT (alanine aminotransferase)/AST (aspartate aminotransferase) <3 fold normal; Bilirubin <2.5mg/dl
Creatinine <2.5mg/dl. ALT (alanine aminotransferase)/AST (aspartate aminotransferase) <3 fold normal. Bilirubin <2.5mg/dl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02259556 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-CD30 antibody disqualifies patients from enrollment.
Does this trial require CD30?
Yes, CD30 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 16 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages